Selected article for: "cardiovascular disease and heart failure"

Author: Aggarwal, Gaurav; Henry, Brandon Michael; Aggarwal, Saurabh; Bangalore, Sripal
Title: Cardiovascular Safety of Potential Drugs for the Treatment of Coronavirus Disease 2019
  • Cord-id: 01es0zv4
  • Document date: 2020_5_16
  • ID: 01es0zv4
    Snippet: Coronavirus disease 2019 (COVID-19) has become a global pandemic. It is still uncontrolled in most countries and no therapies are currently available. Various drugs are under investigation for its treatment. The disease is known to have worse outcomes in patients who have underlying cardiovascular disease. Chloroquine/hydroxychloroquine, azithromycin, remdesivir and lopinavir/ritonavir are currently being studied in trials and show some promise. Conduction disorders, heart failure and mortality
    Document: Coronavirus disease 2019 (COVID-19) has become a global pandemic. It is still uncontrolled in most countries and no therapies are currently available. Various drugs are under investigation for its treatment. The disease is known to have worse outcomes in patients who have underlying cardiovascular disease. Chloroquine/hydroxychloroquine, azithromycin, remdesivir and lopinavir/ritonavir are currently being studied in trials and show some promise. Conduction disorders, heart failure and mortality have been reported with the use of these drugs. It is important to have a knowledge of potential cardiotoxic effects of these drugs before using them for COVID-19 patients for better allocation of healthcare resources and improvement in clinical outcomes.

    Search related documents:
    Co phrase search for related documents
    • ace inhibitor and low density: 1, 2
    • ace inhibitor and low density lipoprotein: 1, 2
    • lopinavir ritonavir and low density: 1, 2
    • lopinavir ritonavir and low density lipoprotein: 1
    • lopinavir ritonavir and lupus erythematosus: 1, 2, 3, 4
    • lopinavir ritonavir and macrolide antibiotic: 1, 2
    • lopinavir ritonavir and magnetic resonance: 1, 2, 3, 4, 5
    • lopinavir ritonavir and magnetic resonance imaging: 1, 2, 3, 4
    • lopinavir ritonavir group and low density: 1
    • lopinavir ritonavir therapy and macrolide antibiotic: 1
    • lopinavir ritonavir therapy and magnetic resonance: 1
    • lopinavir ritonavir therapy and magnetic resonance imaging: 1
    • low density and lupus erythematosus: 1, 2, 3
    • low density and magnetic resonance: 1, 2, 3, 4, 5, 6, 7, 8
    • low density and magnetic resonance imaging: 1, 2, 3, 4
    • low density lipoprotein and lupus erythematosus: 1, 2
    • low density lipoprotein and magnetic resonance: 1, 2, 3, 4
    • lupus erythematosus and magnetic resonance: 1, 2, 3, 4
    • lupus erythematosus and magnetic resonance imaging: 1, 2